Formycon AG
Stephanie Kohlmann has extensive experience in quality management and compliance within the pharmaceutical industry. Currently serving as Senior Manager of Quality Management at Formycon AG since December 2015, Stephanie has held various leadership roles including Manager of Quality Management and Manager of GMP Compliance. Previous professional experience includes a position as Project Manager for Animal Facilities at Helmholtz Zentrum München and over a decade as Associate Scientist in In Vivo Pharmacology at Ingenium Pharmaceuticals AG. Stephanie also completed advanced training in Life Science Management at ATV Ausbildung Training Vernetzung GmbH, focusing on areas such as health care policy, regulatory affairs, and quality assurance. Stephanie holds a Diplom in Biology from Ludwig-Maximilians-Universität München, obtained in 2000.
This person is not in any teams
This person is not in any offices
Formycon AG
1 followers
Who we are Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207 About Biosimilars: Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of approximately USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. Global sales of biosimilars are estimated to exceed $15 billion by 2020. By 2030, analysts estimate that this figure could rise to over $60 billion. Contact: Formycon AG Fraunhoferstr. 15 82152 Martinsried/Planegg Germany phone +49 (0) 89 - 86 46 67 100 fax + 49 (0) 89 - 86 46 67 110 info@formycon.com